Literature DB >> 26169581

Non-Invasive Intravital Imaging of siRNA-Mediated Mutant Keratin Gene Repression in Skin.

Robyn P Hickerson1,2, Tycho J Speaker1, Maria Fernanda Lara1,3, Emilio González-González4,5,6, Manuel A Flores1, Christopher H Contag4,5,7,8, Roger L Kaspar9.   

Abstract

PURPOSE: Small interfering RNAs (siRNAs) specifically and potently inhibit target gene expression. Pachyonychia congenita (PC) is a skin disorder caused by mutations in genes encoding keratin (K) 6a/b, K16, and K17, resulting in faulty intermediate filaments. A siRNA targeting a single nucleotide, PC-relevant mutation inhibits K6a expression and has been evaluated in the clinic with encouraging results. PROCEDURES: To better understand the pathophysiology of PC, and develop a model system to study siRNA delivery and visualize efficacy in skin, wild type (WT) and mutant K6a complementary DNAs (cDNAs) were fused to either enhanced green fluorescent protein or tandem tomato fluorescent protein cDNA to allow covisualization of mutant and WT K6a expression in mouse footpad skin using a dual fluorescence in vivo confocal imaging system equipped with 488 and 532 nm lasers.
RESULTS: Expression of mutant K6a/reporter resulted in visualization of keratin aggregates, while expression of WT K6a/reporter led to incorporation into filaments. Addition of mutant K6a-specific siRNA resulted in inhibition of mutant, but not WT, K6a/reporter expression.
CONCLUSIONS: Intravital imaging offers subcellular resolution for tracking functional activity of siRNA in real time and enables detailed analyses of therapeutic effects in individual mice to facilitate development of nucleic acid-based therapeutics for skin disorders.

Entities:  

Keywords:  Gene regulation; Gene therapy; Genodermatosis; In vivo confocal fluorescence microscopy

Mesh:

Substances:

Year:  2016        PMID: 26169581     DOI: 10.1007/s11307-015-0875-z

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  32 in total

1.  Generic and personalized RNAi-based therapeutics for a dominant-negative epidermal fragility disorder.

Authors:  Deena M Leslie Pedrioli; Dun Jack Fu; Emilio Gonzalez-Gonzalez; Christopher H Contag; Roger L Kaspar; Frances J D Smith; W H Irwin McLean
Journal:  J Invest Dermatol       Date:  2012-03-08       Impact factor: 8.551

2.  Inhibition of CD44 gene expression in human skin models, using self-delivery short interfering RNA administered by dissolvable microneedle arrays.

Authors:  Maria Fernanda Lara; Emilio González-González; Tycho J Speaker; Robyn P Hickerson; Devin Leake; Leonard M Milstone; Christopher H Contag; Roger L Kaspar
Journal:  Hum Gene Ther       Date:  2012-06-05       Impact factor: 5.695

Review 3.  The phenotypic and molecular genetic features of pachyonychia congenita.

Authors:  W H Irwin McLean; C David Hansen; Mark J Eliason; Frances J D Smith
Journal:  J Invest Dermatol       Date:  2011-03-24       Impact factor: 8.551

4.  First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.

Authors:  Sancy A Leachman; Robyn P Hickerson; Mary E Schwartz; Emily E Bullough; Stephen L Hutcherson; Kenneth M Boucher; C David Hansen; Mark J Eliason; G Susan Srivatsa; Douglas J Kornbrust; Frances Jd Smith; Wh Irwin McLean; Leonard M Milstone; Roger L Kaspar
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

5.  Single-nucleotide-specific siRNA targeting in a dominant-negative skin model.

Authors:  Robyn P Hickerson; Frances J D Smith; Robert E Reeves; Christopher H Contag; Devin Leake; Sancy A Leachman; Leonard M Milstone; W H Irwin McLean; Roger L Kaspar
Journal:  J Invest Dermatol       Date:  2007-10-11       Impact factor: 8.551

6.  Delivery and inhibition of reporter genes by small interfering RNAs in a mouse skin model.

Authors:  Qian Wang; Heini Ilves; Pauline Chu; Christopher H Contag; Devin Leake; Brian H Johnston; Roger L Kaspar
Journal:  J Invest Dermatol       Date:  2007-05-24       Impact factor: 8.551

7.  Allele-specific siRNA silencing for the common keratin 12 founder mutation in Meesmann epithelial corneal dystrophy.

Authors:  Edwin H A Allen; Sarah D Atkinson; Haihui Liao; Jonathan E Moore; Deena M Leslie Pedrioli; Frances J D Smith; W H Irwin McLean; C B Tara Moore
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-17       Impact factor: 4.799

8.  The role of confocal microscopy in the dermato-oncology practice.

Authors:  A Diaconeasa; D Boda; M Neagu; C Constantin; C Căruntu; L Vlădău; D Guţu
Journal:  J Med Life       Date:  2011-02-25

9.  Visualization of plasmid delivery to keratinocytes in mouse and human epidermis.

Authors:  Emilio González-González; Yeu-Chun Kim; Tycho J Speaker; Robyn P Hickerson; Ryan Spitler; James C Birchall; Maria Fernanda Lara; Rong-Hua Hu; Yanhua Liang; Nancy Kirkiles-Smith; Mark R Prausnitz; Leonard M Milstone; Christopher H Contag; Roger L Kaspar
Journal:  Sci Rep       Date:  2011-11-15       Impact factor: 4.379

10.  Development of therapeutic siRNAs for pachyonychia congenita.

Authors:  Frances J D Smith; Robyn P Hickerson; Jane M Sayers; Robert E Reeves; Christopher H Contag; Devin Leake; Roger L Kaspar; W H Irwin McLean
Journal:  J Invest Dermatol       Date:  2007-08-30       Impact factor: 8.551

View more
  2 in total

Review 1.  Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior.

Authors:  Miles A Miller; Ralph Weissleder
Journal:  Adv Drug Deliv Rev       Date:  2016-06-04       Impact factor: 15.470

2.  High-Throughput Screening for Drugs that Modulate Intermediate Filament Proteins.

Authors:  Jingyuan Sun; Vincent E Groppi; Honglian Gui; Lu Chen; Qing Xie; Li Liu; M Bishr Omary
Journal:  Methods Enzymol       Date:  2015-11-19       Impact factor: 1.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.